Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 500

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells

Open access
Kebriaei, Partow, Singh, Harjeet, Huls, M. Helen, Figliola, Matthew J., Bassett, Roland, Olivares, Simon, Jena, Bipulendu, Dawson, Margaret J., Kumaresan, Pappanaicken R., Su, Shihuang, Maiti, Sourindra, Dai, Jianliang, Moriarity, Branden, Forget, Marie-Andrée, Senyukov, Vladimir, Orozco, Aaron, Liu, Tingting, McCarty, Jessica, Jackson, Rineka N., Moyes, Judy S., Rondon, Gabriela, Qazilbash, Muzaffar, Ciurea, Stefan, Alousi, Amin, Nieto, Yago, Rezvani, Katy, Marin, David, Popat, Uday, Hosing, Chitra, Shpall, Elizabeth J., Kantarjian, Hagop, Keating, Michael, Wierda, William, Do, Kim Anh, Largaespada, David A., Lee, Dean A., Hackett, Perry B., Champlin, Richard E., Cooper, Laurence J.N.·2016·Journal of Clinical Investigation

Abstract

BACKGROUND: T cells expressing antigen-specific chimeric antigen receptors (CARs) improve outcomes for CD19-expressing B cell malignancies. We evaluated a human application of T cells that were genetically modified using the Sleeping Beauty (SB) transposon/transposase system to express a CD19-specific CAR. METHODS: T cells were genetically modified using DNA plasmids from the SB platform to stably express a second-generation CD19-specific CAR and selectively propagated ex vivo with activating and propagating cells (AaPCs) and cytokines. Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia safely underwent hematopoietic stem cell transplantation (HSCT) and infusion of CAR T cells as adjuvant therapy in the autologous (n = 7) or allogeneic settings (n = 19). RESULTS: SB-mediated genetic transposition and stimulation resulted in 2,200- to 2,500-fold ex vivo expansion of genetically modified T cells, with 84% CAR expression, and without integration hotspots. Following autologous HSCT, the 30-month progression-free and overall survivals were 83% and 100%, respectively. After allogeneic HSCT, the respective 12-month rates were 53% and 63%. No acute or late toxicities and no exacerbation of graft-versus-host disease were observed. Despite a low antigen burden and unsupportive recipient cytokine environment, CAR T cells persisted for an average of 201 days for autologous recipients and 51 days for allogeneic recipients. CONCLUSIONS: CD19-specific CAR T cells generated with SB and AaPC platforms were safe, and may provide additional cancer control as planned infusions after HSCT. These results support further clinical development of this nonviral gene therapy approach. TRIAL REGISTRATION: Autologous, NCT00968760; allogeneic, NCT01497184; long-term follow-up, NCT01492036. FUNDING: National Cancer Institute, private foundations, and institutional funds. Please see Acknowledgments for details.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci86721

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 500

Metadata

Authors
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., Maiti, S., Dai, J., Moriarity, B., Forget, M.-A., Senyukov, V., Orozco, A., Liu, T., McCarty, J., Jackson, R. N., Moyes, J. S., Rondon, G., Qazilbash, M., Ciurea, S., Alousi, A., Nieto, Y., Rezvani, K., Marin, D., Popat, U., Hosing, C., Shpall, E. J., Kantarjian, H., Keating, M., Wierda, W., Do, K. A., Largaespada, D. A., Lee, D. A., Hackett, P. B., Champlin, R. E., & Cooper, L. J. N.
Venue
Journal of Clinical Investigation
Published
2016-08-02
Volume
126
Issue
9
Pages
3363-3376
ISSN
  • 0021-9738 (ISSN-L)
  • 1558-8238
OpenAlex
W2500107307
Cited by
500
References
59
FWCI
29.05
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. https://app.cochat.ai/papers/10.1172/jci86721
The paper
Kebriaei, P., Singh, H., Huls, M. H., Figliola, M. J., Bassett, R., Olivares, S., Jena, B., Dawson, M. J., Kumaresan, P. R., Su, S., Maiti, S., Dai, J., Moriarity, B., Forget, M.-A., Senyukov, V., Orozco, A., Liu, T., McCarty, J., Jackson, R. N., . . . Cooper, L. J. N. (2016). Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci86721

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.